Yahoo

Study Finds the Corus(R) CAD Gene Expression Blood Test Influenced Primary Care Decision-Making in the Assessment of Patients With Suspected Obstructive Coronary Artery Disease

PALO ALTO, CA--(Marketwired - Mar 10, 2014) - CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, today announced the publication of the IMPACT-PCP (Investigation ...
Yahoo Finance

New Study Results Further Reinforce That the Corus(R) CAD Test Helps Primary Care Clinicians Make Effective Referral Decisions for Patients With Suspected Obstructive Coronary ...

Patients With a Low Corus CAD Score Had 94% Reduced Odds of Referral to a Cardiologist; REGISTRY I Study Results Add to the Established Evidence Base Supporting the Clinical Utility of the Corus CAD ...
FierceBiotech

Study: Corus CAD demonstrates superiority to MPI

CardioDx saw good news from Florida this week with the presentation of results from the COMPASS trial involving Corus CAD, a blood-based gene expression test for obstructive coronary artery disease.
TCTMD

Study Highlights Clinical Risk of Nonobstructive CAD

Patients diagnosed with nonobstructive coronary artery disease (CAD) are at increased risk of myocardial infarction (MI) and mortality over the next year compared with those classified as having no ...
Yahoo Finance

CardioDx Announces Results of Study Demonstrating the Benefits of the Corus CAD Gene Expression Test Use in an African American Patient Population

REDWOOD CITY, CA--(Marketwired - Oct 20, 2014) - CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, today announced the presentation of the study, "The Use of a ...
FierceBiotech

Large study finds 5 genes associated with CAD

A study published in PLoS Genetics identifies 5 genes that are associated with developing coronary artery disease (CAD) and heart attacks. CAD is a leading cause of premature death worldwide, and the ...
BioWorld

EMPOWER CAD study confirms benefits of IVL-first strategy in women

Shockwave Medical Inc., a unit of Johnson & Johnson Medtech, reported positive 30-day results from the EMPOWER CAD trial, which used its intravascular lithotripsy system in women with complex, ...